Search Results
Your search for Matthew Stenger matches 7644 pages
Showing 1001 - 1050Immune Checkpoint Inhibition and Long-Term Survival in Patients With Metastatic Urothelial Cancer
In an analysis reported in JAMA Network Open, Zhu et al found that immune checkpoint inhibitor treatment did not appear to be associated with long-term survival in patients with metastatic urothelial cancer. Study Details The analysis included data from six trials of pembrolizumab, avelumab, and...
Psilocybin Therapy for Patients With Cancer and Major Depression Disorder
In a phase II study reported in a research letter in JAMA Oncology, Agrawal et al found that a single treatment with psilocybin (COMP360) with a 1:1 therapist-to-patient ratio reduced symptoms of depression in patients with cancer and major depression disorder treated at a single community cancer...
Preoperative Peritumoral Infiltration of Local Anesthetic in Patients With Early Breast Cancer: Effect on Survival
In an Indian trial reported in the Journal of Clinical Oncology, Badwe et al found that peritumoral infiltration of local anesthetic prior to surgery in patients with early breast cancer was associated with improved disease-free and overall survival. As stated by the investigators, “Preventing...
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer
As reported in JAMA Oncology by Tang et al, the phase II EXTEND (External Beam Radiation to Eliminate Nominal Metastatic Disease) trial has shown that the addition of metastasis-directed therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic...
MRD and KMT2A Fusion Partners in Predicting Outcomes of Childhood KMT2A-Rearranged Acute Myeloid Leukemia
In a retrospective study reported in the Journal of Clinical Oncology, van Weelderen et al, of the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG), found that KMT2A fusion partners and measurable residual disease (MRD) at end of induction phase 2 were independent predictors of...
Addition of Abiraterone Acetate and Prednisone to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Michael J. Morris, MD, and colleagues, the phase III Alliance A031201 trial has shown no significant improvement in overall survival with the addition of abiraterone acetate and prednisone to enzalutamide as first-line treatment for metastatic...
Pathologic Complete Response and Outcomes in Localized Soft-Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy
In an analysis reported in JAMA Oncology, Wang et al found that pathologic complete response (pCR) was associated with improved outcomes among patients with localized soft-tissue sarcoma receiving neoadjuvant chemoradiotherapy or radiotherapy. The analysis included data from patients from two RTOG...
Belzutifan Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma Previously Treated With PD-1 or PD-L1 Inhibitors
In a U.S. phase II trial reported in The Lancet Oncology, Toni K. Choueiri, MD, and colleagues found that the combination of the hypoxia-inducible factor 2α inhibitor belzutifan and the VEGFR kinase inhibitor cabozantinib showed promising activity in patients with advanced clear cell renal cell...
Confirmatory Mediastinoscopy vs Immediate Resection After Endosonography for Resectable NSCLC
In a trial (MEDIASTrial) reported in the Journal of Clinical Oncology, Bousema et al found that immediate lung tumor resection after negative systematic endosonography was noninferior to confirmatory mediastinoscopy in the detection of unforeseen N2 disease in patients with non–small cell lung...
Addition of Ipilimumab to Nivolumab in Recurrent or Metastatic Head and Neck Cancer
As reported in JAMA Oncology by Kevin J. Harrington, MBBS, PhD, and colleagues, the phase II CheckMate 714 trial has shown that the addition of ipilimumab to nivolumab did not improve objective response rate as first-line treatment in patients with recurrent or metastatic squamous cell carcinoma of ...
Consensus Molecular Subtypes as Markers for Maintenance Therapy Regimens for RAS Wild-Type Metastatic Colorectal Cancer
In an analysis of the German phase II PanaMa trial reported in the Journal of Clinical Oncology, Stahler et al evaluated consensus molecular subtypes as prognostic and predictive biomarkers in patients with RAS wild-type metastatic colorectal cancer receiving fluorouracil and leucovorin with or...
GD2-CAR T Cells for Relapsed or Refractory High-Risk Neuroblastoma
In a single-institution Italian phase I/II trial reported in The New England Journal of Medicine, Del Bufalo et al found that treatment with chimeric antigen receptor (CAR) T cells targeting the disialoganglioside GD2 expressed on tumor cells (GD2-CART01) produced responses in pediatric patients...
Pathologic Complete Response as Surrogate for Event-Free and Overall Survival in Neoadjuvant Trials in HER2-Positive Early Breast Cancer
In a study reported in the Journal of Clinical Oncology, Squifflet et al found that pathologic complete response (pCR) was a weak surrogate for event-free and overall survival in neoadjuvant trials of anti-HER2 therapy in patients with HER2-positive early breast cancer. Study Details In the study,...
Mortality After Colonoscopy-Detected vs Postcolonoscopy-Diagnosed Colorectal Cancer in the VA Health-Care System
In a study reported in JAMA Network Open, Kahi et al found no differences in all-cause or cancer-specific mortality among veterans in the Veterans Affairs (VA) health-care system with colonoscopy-detected colorectal cancer vs those with postcolonoscopy-diagnosed colorectal cancer. Study Details...
Endoscopic Surveillance in Patients at Risk for Hereditary Diffuse Gastric Cancer
In a prospective cohort study reported in The Lancet Oncology, Asif et al found that endoscopic surveillance may be an alternative to prophylactic total gastrectomy in patients at risk for hereditary diffuse gastric cancer due to germline CDH1 pathogenic variants. Study Details In the study, 270...
Olanzapine to Prevent Chemotherapy-Related Anorexia in Newly Diagnosed Patients With Advanced Cancers
In an Indian single-center study reported in the Journal of Clinical Oncology, Sandhya et al found that olanzapine was associated with weight gain and improved appetite vs placebo in patients receiving chemotherapy for newly diagnosed locally advanced or metastatic gastric,...
T-DXd in HER2-Expressing Advanced or Recurrent Uterine Carcinosarcoma
In a Japanese phase II trial (STATICE) reported in the Journal of Clinical Oncology, Nishikawa et al found that fam-trastuzumab deruxtecan-nxki (T-DXd) showed activity in patients with HER2-expressing advanced or recurrent uterine carcinosarcoma. Study Details In the multicenter trial, 32 evaluable ...
Interaction of H pylori Infection and Germline Pathogenic Variants in Risk for Gastric Cancer
In a Japanese study reported in The New England Journal of Medicine, Usui et al found that Helicobacter pylori infection affected the risk of gastric cancer in patients with predisposing germline pathogenic variants, including variants in homologous recombination genes. As stated by the...
Abemaciclib Expanded Indication for Adjuvant Use in HR-Positive, HER2-Negative, Node-Positive Early Breast Cancer
On March 3, 2023, abemaciclib was approved for use with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of patients with hormone receptor (HR)-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence.1 Abemaciclib was previously approved...
Effect of Smoking Cessation After Diagnosis of Renal Cell Carcinoma on Disease Progression and Survival Outcomes
In a Russian single-institution prospective cohort study reported in the Journal of Clinical Oncology, Sheikh et al found that quitting smoking after a diagnosis of renal cell carcinoma (RCC) was associated with improved disease progression and survival outcomes among patients. Study Details The...
Primary Overall Survival Analysis of the ENZAMET Trial in Metastatic Hormone-Sensitive Prostate Cancer
As reported in The Lancet Oncology by Christopher J. Sweeney, MBBS, and colleagues, the primary overall survival analysis of the phase III ENZAMET trial showed a significant benefit with enzalutamide plus testosterone suppression vs standard nonsteroidal antiandrogen treatment plus testosterone...
Addition of Toripalimab to Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
In a Chinese single-center phase II trial (EC-CRT-001) reported in The Lancet Oncology, Zhu et al found that the addition of the PD-1 inhibitor toripalimab to definitive chemoradiotherapy resulted in “encouraging activity and acceptable toxicity” in patients with locally advanced esophageal...
Risk of Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer
In a phase II trial (ACOSOG Z11102/Alliance) reported in the Journal of Clinical Oncology, Judy C. Boughey, MD, and colleagues found that breast-conserving therapy was associated with a low rate of local recurrence in women with multiple ipsilateral breast cancer sites. Study Details A total of 204 ...
Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Julie E. Bauman, MD, MPH, and colleagues found that the combination of the antihepatocyte growth factor antibody ficlatuzumab and cetuximab was active in patients with cetuximab-resistant, recurrent or metastatic head and neck...
Addition of Niraparib to Abiraterone Acetate and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Kim N. Chi, MD, and colleagues, the phase III MAGNITUDE trial showed that the addition of niraparib to abiraterone acetate and prednisone improved radiographic progression–free survival as first-line treatment in patients with metastatic...
Addition of Bortezomib to R-CHOP in Patients With DLBCL According to Molecular Subgroups: 5-Year Follow-up of the REMoDL-B Study
In a 5-year analysis of the UK/Swiss phase III REMoDL-B trial reported in the Journal of Clinical Oncology, Davies et al found that the addition of bortezomib to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; RB-CHOP) as initial treatment was associated with...
Prognostic Performance of a Molecular International Prognostic Scoring System for MDS
In a European study reported in the Journal of Clinical Oncology, Sauta et al found that the recently devised Molecular International Prognostic Scoring System (IPSS-M) had improved prognostic ability vs the standard Revised International Prognostic Scoring System (IPSS-R) in patients with...
Hypercalcemia in Patients With Cholangiocarcinoma
In a study reported in a research letter in JAMA Oncology, Konstantinidou et al found that the prevalence of hypercalcemia increased over time in patients with cholangiocarcinoma and was significantly more common in those with IDH1-mutant intrahepatic disease. Study Details The study involved...
Effect of Insurance Status on Racial and Ethnic Inequities in the Diagnosis of Advanced-Stage Cervical Cancer
In a study reported in JAMA Network Open, Holt et al found that health insurance status was a substantial mediator in the diagnosis of advanced-stage vs early-stage cervical cancer across ethnicity and race in patients from the United States. Study Details The retrospective, cross-sectional,...
Extended Performance of an Image-Based Short-Term Risk Model for Predicting Breast Cancer
In a Swedish case-cohort study reported in the Journal of Clinical Oncology, Eriksson et al found that an image-based short-term risk model outperformed a traditional lifestyle/familial risk–based risk model in predicting the likelihood of development of breast cancer over a 10-year period. Study...
How Do Novel Genetic Subtypes of Urothelial Carcinoma Respond to Immune Checkpoint Blockade?
In a study reported in the Journal of Clinical Oncology, Sarfaty et al identified novel genetic subtypes of urothelial carcinoma exhibiting different responses to immune checkpoint blockade. Study Details In the multicenter study, whole-exome sequencing was performed on tumor specimens from 88...
Subcutaneous vs IV Administration of Medications and Fluids in Patients With Cancer: U.S. vs Canadian Cancer Center Methods
In a study reported in a research letter in JAMA Oncology, Tang et al found that the use of the subcutaneous route for administering medications and fluids in patients with cancer was highly predominant in a Canadian center, whereas use of the intravenous (IV) route was nearly universal in a U.S....
Antibiotic Use and Survival Among Patients With Metastatic Pancreatic Cancer Receiving Specific Chemotherapy Regimens
In a retrospective cohort study reported in JAMA Network Open, Fulop et al found that perichemotherapy use of antibiotics was associated with improved survival in patients with metastatic pancreatic ductal adenocarcinoma receiving first-line gemcitabine-based chemotherapy, but not in those...
Lower-Dose Regimens of Exemestane in Postmenopausal Patients With Stage 0 to II ER-Positive Breast Cancer
In a phase IIb trial reported in JAMA Oncology, Serrano et al found that exemestane at 25 mg three times weekly was noninferior to the standard dosing of 25 mg once daily in terms of serum estradiol reduction among postmenopausal patients with stage 0 to II estrogen receptor (ER)-positive breast...
New Prognostic Staging System for De Novo Metastatic Breast Cancer
In a study reported in the Journal of Clinical Oncology, Jennifer K. Plichta, MD, MS, and colleagues formulated a novel prognostic staging system for de novo metastatic breast cancer. Study Details The staging system was developed using data from 42,467 patients from the National Cancer Database...
Change in Frailty Status Among Older Patients Undergoing Locoregional Therapy for Early-Stage Breast Cancer
In a cohort study reported in a research letter in JAMA Surgery, Minami et al found that frailty status worsened in a sizable proportion of older patients receiving locoregional therapy—including lumpectomy or mastectomy—for early-stage breast cancer. Baseline robust status and mastectomy were...
Naporafenib Plus Trametinib in Advanced NRAS-Mutant Melanoma
As reported in the Journal of Clinical Oncology by de Braud et al, findings in the expansion cohort of a phase Ib trial indicate activity with the combination of the BRAF/CRAF kinase inhibitor naporafenib and trametinib in patients with advanced or metastatic NRAS-mutant melanoma. Study Details In ...
Significance of the MGUS-Like Phenotype in Patients With Multiple Myeloma and Light Chain Amyloidosis
In a study reported in the Journal of Clinical Oncology, Burgos et al developed an algorithm to identify patients with multiple myeloma and light-chain amyloidosis who have the monoclonal gammopathy of undetermined significance (MGUS)-like phenotype, as well as identified the association of the...
Poorer Survival in Stage III Colon Cancer With Greater Inflammation After Surgery and Prior to Adjuvant Therapy
In a study reported in JAMA Oncology, En Cheng, MD, PhD, of Kaiser Permanente Northern California, Jeffrey Meyerhardt, MD, MPH, FASCO, of Dana-Farber Cancer Institute, and colleagues found that higher levels of inflammatory biomarkers measured after surgery but before starting chemotherapy were ...
Smoking Cessation Intervention in Patients With a History of Cervical Intraepithelial Neoplasia or Cervical Cancer
In a study reported in the Journal of Clinical Oncology, Vidrine et al found that a smoking cessation intervention was not effective among patients with a history of cervical intraepithelial neoplasia or cervical cancer. Study Details In the trial, 194 evaluable patients who reported current...
First-Line Systemic Treatments in Metastatic Castration-Sensitive Prostate Cancer
In a systematic review and meta-analysis reported in JAMA Oncology, Riaz et al found that first-line triplet therapy in metastatic castration-sensitive prostate cancer did not appear to offer an overall survival advantage vs androgen pathway inhibitor doublet therapy. As stated by the...
DESTINY-Breast03: T-DXd Improves Overall Survival vs T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer
As reported in The Lancet by Sara A. Hurvitz, MD, of the David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, and colleagues, updated results of the phase III DESTINY-Breast03 trial showed significantly improved overall survival with...
Sotorasib Improves Progression-Free Survival vs Docetaxel in Previously Treated Advanced NSCLC With KRAS G12C Mutation
As reported in The Lancet by Adrianus Johannes de Langen, MD, PhD, of the Netherlands Cancer Institute, Amsterdam, and colleagues, the phase III CodeBreaK200 trial has shown a small but significant improvement in progression-free survival with sotorasib vs docetaxel in previously treated advanced...
Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma
As reported in The New England Journal of Medicine by Paula Rodriguez-Otero, MD, PhD, of Clínica Universidad de Navarra, Pamplona, Spain, and colleagues, an interim analysis of the phase III KarMMa-3 trial has shown superior progression-free survival with the B-cell maturation antigen–directed...
Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
On January 27, 2023, pirtobrutinib was granted accelerated approval for treatment of relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.1 Pirtobrutinib is a noncovalent inhibitor of BTK. Supporting Efficacy...
Regular Approval for Dostarlimab-gxly in dMMR Recurrent or Advanced Endometrial Cancer
On February 9, 2023, dostarlimab-gxly was granted regular approval for adults with mismatch repair–deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a U.S. Food and Drug Administration–approved test, whose disease has progressed on or following a prior platinum-containing...
Association of Baseline and Subsequent Cardiovascular Health Metrics to Risk for Incident Cancers
In an analysis from the French GAZEL study reported in JACC: CardioOncology, Thomas Van Sloten, MD, PhD, of the Université Paris Cité, Institut National de la Santé et de la Recherche Médicale, Paris, and colleagues found that better cardiovascular health (CVH) scores at baseline and improvement in ...
Racial/Ethnic Disparities in All-Cause and Cardiovascular Mortality Among U.S. Patients With Cancer
In an analysis reported in JACC: CardioOncology, Cenjing Zhu, MPhil, of the Department of Chronic Disease Epidemiology, Yale University, and colleagues found that Black patients with cancer in the United States were at increased risk of all-cause mortality and cardiovascular (CVD) mortality...
Rucaparib vs Physician’s Choice of Single-Agent Therapy in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the...
Adjuvant Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation in Early Breast Cancer: 10 Year Outcomes of Phase III Study
As reported in The Lancet Oncology by Vratislav Strnad, MD, PhD, of University Hospital Erlangen and Comprehensive Cancer Center Erlangen, Germany, and colleagues, 10-year outcomes in a phase III GEC-ESTRO (Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology) trial...
